Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):175–179. doi: 10.1128/aac.39.1.175

Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus.

F Parras 1, M C Guerrero 1, E Bouza 1, M J Blázquez 1, S Moreno 1, M C Menarguez 1, E Cercenado 1
PMCID: PMC162505  PMID: 7695302

Abstract

Mupirocin is a topically applied drug that is very active in the eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). However, studies designed to compare mupirocin treatment with other antimicrobial regimens are lacking. We therefore conducted an open, prospective, randomized, controlled trial to compare the efficacy and safety of mupirocin versus those of oral co-trimoxazole plus topical fusidic acid (both regimens with a clorhexidine scrub bath) for the eradication of MRSA from nasal and extranasal carriers of MRSA. The eradication rates with mupirocin and co-trimoxazole plus fusidic acid at 2, 7, 14, 21, 28, and 90 days were 93 and of 93, 100 and 100, 97 and 94, 100 and 92, 96 and 95, and 78 and 71%, respectively, for nasal carriage. At 7, 14, and 28 days the eradication rates for extranasal carriage by the two regimens were 23 and 74, 83 and 76, and 45 and 69%, respectively. The efficacies and safety of both regimens were similar. The MRSA isolates were not resistant to the study drugs either at the baseline or at follow-up. These results suggest that mupirocin and co-trimoxazole plus fusidic acid, both used in conjunction with a chlorhexidine soap bath, are equally effective and safe for the eradication of MRSA from nasal and extranasal MRSA carriers. Mupirocin was easier to use but was more expensive.

Full Text

The Full Text of this article is available as a PDF (203.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyce J. M. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am. 1989 Dec;3(4):901–913. [PubMed] [Google Scholar]
  2. Casewell M. W., Hill R. L. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial. J Antimicrob Chemother. 1986 Mar;17(3):365–372. doi: 10.1093/jac/17.3.365. [DOI] [PubMed] [Google Scholar]
  3. Casewell M. W., Hill R. L. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1985 May;15(5):523–531. doi: 10.1093/jac/15.5.523. [DOI] [PubMed] [Google Scholar]
  4. Davies E. A., Emmerson A. M., Hogg G. M., Patterson M. F., Shields M. D. An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control. J Hosp Infect. 1987 Sep;10(2):120–128. doi: 10.1016/0195-6701(87)90137-x. [DOI] [PubMed] [Google Scholar]
  5. Frank U., Lenz W., Damrath E., Kappstein I., Daschner F. D. Nasal carriage of Staphylococcus aureus treated with topical mupirocin (pseudomonic acid) in a children's hospital. J Hosp Infect. 1989 Feb;13(2):117–120. doi: 10.1016/0195-6701(89)90017-0. [DOI] [PubMed] [Google Scholar]
  6. GODTFREDSEN W., ROHOLT K., TYBRING L. Fucidin: a new orally active antibiotic. Lancet. 1962 May 5;1(7236):928–931. doi: 10.1016/s0140-6736(62)91968-2. [DOI] [PubMed] [Google Scholar]
  7. Hill R. L., Duckworth G. J., Casewell M. W. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother. 1988 Sep;22(3):377–384. doi: 10.1093/jac/22.3.377. [DOI] [PubMed] [Google Scholar]
  8. Humble M. W., Eykyn S., Phillips I. Staphylococcal bacteraemia, fusidic acid, and jaundice. Br Med J. 1980 Jun 21;280(6230):1495–1498. doi: 10.1136/bmj.280.6230.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kauffman C. A., Terpenning M. S., He X., Zarins L. T., Ramsey M. A., Jorgensen K. A., Sottile W. S., Bradley S. F. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med. 1993 Apr;94(4):371–378. doi: 10.1016/0002-9343(93)90147-h. [DOI] [PubMed] [Google Scholar]
  10. Markowitz N., Pohlod D. J., Saravolatz L. D., Quinn E. L. In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981. Antimicrob Agents Chemother. 1983 Mar;23(3):450–457. doi: 10.1128/aac.23.3.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mupirocin-resistant Staphylococcus aureus. Lancet. 1987 Aug 15;2(8555):387–388. [PubMed] [Google Scholar]
  12. Parras F., Rodríguez M., Bouza E., Muñoz P., Cercenado E., Guerrero C., Zancada G. Brote epidémico de Staphylococcus aureus resistente a meticilina (SARM) en un hospital general. Informe preliminar. Enferm Infecc Microbiol Clin. 1991 Apr;9(4):200–207. [PubMed] [Google Scholar]
  13. Reagan D. R., Doebbeling B. N., Pfaller M. A., Sheetz C. T., Houston A. K., Hollis R. J., Wenzel R. P. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med. 1991 Jan 15;114(2):101–106. doi: 10.7326/0003-4819-114-2-101. [DOI] [PubMed] [Google Scholar]
  14. Roccaforte J. S., Bittner M. J., Stumpf C. A., Preheim L. C. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin. Am J Infect Control. 1988 Aug;16(4):141–146. doi: 10.1016/0196-6553(88)90024-7. [DOI] [PubMed] [Google Scholar]
  15. Sande M. A., Mandell G. L. Effect of rifampin on nasal carriage of Staphylococcus aureus. Antimicrob Agents Chemother. 1975 Mar;7(3):294–297. doi: 10.1128/aac.7.3.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Smith G. E., Kennedy C. T. Staphylococcus aureus resistant to mupirocin. J Antimicrob Chemother. 1988 Jan;21(1):141–142. doi: 10.1093/jac/21.1.141. [DOI] [PubMed] [Google Scholar]
  17. Sutherland R., Boon R. J., Griffin K. E., Masters P. J., Slocombe B., White A. R. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495–498. doi: 10.1128/aac.27.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Walsh T. J., Standiford H. C., Reboli A. C., John J. F., Mulligan M. E., Ribner B. S., Montgomerie J. Z., Goetz M. B., Mayhall C. G., Rimland D. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother. 1993 Jun;37(6):1334–1342. doi: 10.1128/aac.37.6.1334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ward A., Campoli-Richards D. M. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986 Nov;32(5):425–444. doi: 10.2165/00003495-198632050-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES